Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
---|---|---|---|---|---|---|---|---|---|---|---|
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 59.0 | 55 | |
RA2159 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 63.0 | 49 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 45.0 | 57 | |
N2645 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 53.0 | 59 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 51.0 | 51 | |
RA2708 | IKK16 | 2.0 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 50.0 | 49 | |
RA2159 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 62.5 | 56 | |
RA2159 | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 69.0 | 60 | ||||
N2645 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 73.0 | 54 | |
N2645 | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 63.0 | 56 | ||||
RA2708 | Tofacitinib | 0.3 | uM | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 59.0 | 48 | |
RA2708 | TNF-a | 100 | ng/mL | 2 | PDGF-BB | 54.0 | 35 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 25.0 | 47 | |
RA2159 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 28.0 | 65 | |
N2645 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 31.0 | 70 | |
N2645 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 31.5 | 66 | |
RA2708 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 24.0 | 45 | |
RA2708 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 32.0 | 79 | |
RA2159 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 54.0 | 63 | |
RA2159 | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 50.0 | 59 | ||||
N2645 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 37.0 | 58 | |
N2645 | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 40.5 | 60 | ||||
RA2708 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 52.0 | 53 | |
RA2708 | IL-1 alpha | 100 | ng/mL | 2 | PDGF-BB | 48.5 | 48 | ||||
RA2159 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 2 | PDGF-BB | 25.0 | 75 |